Johnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis
+1 new source since this summary was written
Johnson & Johnson presented two‑year data from the Phase 3 ICONIC‑LEAD trial of its oral peptide ICOTYDE for moderate‑to‑severe plaque psoriasis. At Week 112, 72% of patients achieved PASI 90 and more than 70% had clear or almost clear skin, with 44% reaching complete clearance. The safety profile remained consistent with earlier reports and no new safety signals were identified.
Why it matters
The company noted that the durable efficacy and safety could position ICOTYDE as a first‑line systemic therapy, potentially expanding its market share in psoriasis treatment. The data prompted a 15% pre‑market rise in JNJ shares (Investing.com) and modest pre‑market price movement thereafter (RTTNews).
Key facts
- 1The ICONIC‑LEAD study enrolled 684 participants (456 on ICOTYDE, 228 on placebo), including 66 adolescents. prnewswire.com
- 2At Week 112, ≥72% of ICOTYDE‑treated patients achieved PASI 90. prnewswire.com
- 3From Week 64 through Week 112, ≥70% of patients achieved clear or almost clear skin (IGA 0/1). prnewswire.com
- 4Complete skin clearance (PASI 100) was sustained in ≥44% of patients, and ≥46% achieved IGA 0. prnewswire.com
- 5Clinically meaningful itch improvement was sustained in 78% of patients. prnewswire.com
- 6Among PASI 90 responders withdrawn at Week 24, 85% regained the response within 24 weeks of retreatment. stocktitan.net
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.